Source-grounded facts extracted from BioAge Labs, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BioAge Labs, Inc. reported first quarter ended March 31, 2026 results: revenue 2.8 million, net income -22.3 million, EPS -0.52.
“with Lilly ExploR&D for the development of therapeutic antibodies targeting novel metabolic aging targets. First Quarter 2026 Financial Results Collaboration revenue was $2.8 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025. The $1.3 million increase in collaboration revenue was due to increased full-time”
BioAge Labs, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters valued at $107.6 million (effective 2026-01-21).
“On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a price of $19.50 per Underwritten Share (the “ Offering ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.